(Total Views: 88)
Posted On: 09/27/2018 2:45:56 PM
Post# of 18416
$GNPX has signed an agreement with Aldevron to supply TUSC2 (Tumor Suppressor Candidate2) plasmid DNA for use in Genprex’s clinical development program evaluating its immunogene therapy Oncoprex™ for the treatment of non-small cell lung cancer. https://finance.yahoo.com/news/genprex-taps-a...00040.html
(0)
(0)
